CoiffierB., HaiounC., KettererN., EngertA., TillyH., MaD.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood, 92: 1927–1932, 1998.
2.
CoiffierB., FerméC., HermineO., HaiounC., BaumelouE.: Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study. Blood, 98: 725a, 2001.
3.
CzuczmanM.S., Grillo- LópezA.J., WhiteC.A., SalehM., GordonL., LoBuglioA.F.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 17: 268–276, 1999.
McLaughlinP., Grillo-LópezA., LinkB.K., LevyR., CzuczmanM.S., WilliamsM.E.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 16: 2825–2833, 1998.
6.
MeyerR.M., BrowmanG.P., SamoshM.L.: Randomised phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol, 13: 2386–2393, 1995.
7.
SonneveldP., De RidderH., Van der Lelie: Comparison of doxorubicin and mixantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol, 13: 2530–2539, 1995.
8.
The Non-Hodgkin's Lymphoma Classification Project:Effect of age on the characteristics and clinical behaviour of non-Hodgkin's lymphoma patients. Ann Oncol, 8: 973–978, 1997.
9.
TillyH., LepageE., CoiffierB.: A randomised comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: the LNH93-5 study. Blood, 96: 832a, 2000.
10.
VoseJ.M., LinkB.K., GrossbardM.L., CzuczmanM., Grillo-LópezA., GilmanP.: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol, 19: 389–397, 2001.
